Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer's Disease.
CSF biomarkers
adiposity
ketogenic diet
mild cognitive impairment
prediabetes
subjective memory complaints
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
03
2022
accepted:
06
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
Ketogenic diets have been used to treat both obesity and neurological disorders, including epilepsy and more recently Alzheimer's disease (AD), likely due to favorable effects on both central and peripheral metabolism. Improvements in body composition have also been reported; however, it is unclear if diet-induced changes in adiposity are related to improvements in AD and related neuropathology. We examined the effects of a Modified Mediterranean Ketogenic (MMK) diet vs. an American Heart Association (AHA) diet on body weight, body composition, and body fat distribution and their association with cerebrospinal fluid (CSF) biomarkers in older adults at risk for AD. Twenty adults (mean age: 64.3 ± 6.3 years, 35% Black, 75% female) were randomly assigned to a crossover trial starting with either the MMK or AHA diet for 6 weeks, followed by a 6-week washout and then the opposite diet for 6 weeks. At baseline and after each diet adiposity was assessed by dual-energy x-ray absorptiometry and CSF biomarkers were measured. Linear mixed effect models were used to examine the effect of diet on adiposity. Spearman correlations were examined to assess associations between adiposity and CSF biomarkers. At baseline there was a high prevalence of overweight/obesity and central adiposity, and higher visceral fat and lower peripheral fat were associated with an adverse CSF biomarker profile. The MMK and AHA diets led to similar improvements in body composition and body fat distribution. Significant correlations were found between changes in adiposity and changes in CSF biomarkers (r's = 0.63-0.92, p's < 0.05), with notable differences by diet. Decreases in body fat on the MMK diet were related to changes in Aβ biomarkers, whereas decreases in body fat on the AHA diet were related to changes in tau biomarkers and cholinesterase activity. Interestingly, increases in CSF Aβ on the MMK diet occurred in those with less fat loss. An MMK diet leads to favorable changes in body composition, body fat distribution, and CSF biomarkers. Our data suggest that modest weight loss that maximizes visceral fat loss and preserves peripheral fat, may have the greatest impact on brain health. [www.ClinicalTrials.gov], identifier [NCT02984540].
Sections du résumé
Background
UNASSIGNED
Ketogenic diets have been used to treat both obesity and neurological disorders, including epilepsy and more recently Alzheimer's disease (AD), likely due to favorable effects on both central and peripheral metabolism. Improvements in body composition have also been reported; however, it is unclear if diet-induced changes in adiposity are related to improvements in AD and related neuropathology.
Purpose
UNASSIGNED
We examined the effects of a Modified Mediterranean Ketogenic (MMK) diet vs. an American Heart Association (AHA) diet on body weight, body composition, and body fat distribution and their association with cerebrospinal fluid (CSF) biomarkers in older adults at risk for AD.
Methods
UNASSIGNED
Twenty adults (mean age: 64.3 ± 6.3 years, 35% Black, 75% female) were randomly assigned to a crossover trial starting with either the MMK or AHA diet for 6 weeks, followed by a 6-week washout and then the opposite diet for 6 weeks. At baseline and after each diet adiposity was assessed by dual-energy x-ray absorptiometry and CSF biomarkers were measured. Linear mixed effect models were used to examine the effect of diet on adiposity. Spearman correlations were examined to assess associations between adiposity and CSF biomarkers.
Results
UNASSIGNED
At baseline there was a high prevalence of overweight/obesity and central adiposity, and higher visceral fat and lower peripheral fat were associated with an adverse CSF biomarker profile. The MMK and AHA diets led to similar improvements in body composition and body fat distribution. Significant correlations were found between changes in adiposity and changes in CSF biomarkers (r's = 0.63-0.92, p's < 0.05), with notable differences by diet. Decreases in body fat on the MMK diet were related to changes in Aβ biomarkers, whereas decreases in body fat on the AHA diet were related to changes in tau biomarkers and cholinesterase activity. Interestingly, increases in CSF Aβ on the MMK diet occurred in those with less fat loss.
Conclusion
UNASSIGNED
An MMK diet leads to favorable changes in body composition, body fat distribution, and CSF biomarkers. Our data suggest that modest weight loss that maximizes visceral fat loss and preserves peripheral fat, may have the greatest impact on brain health.
Clinical Trial Registration
UNASSIGNED
[www.ClinicalTrials.gov], identifier [NCT02984540].
Identifiants
pubmed: 35720727
doi: 10.3389/fnins.2022.906539
pmc: PMC9202553
doi:
Banques de données
ClinicalTrials.gov
['NCT02984540']
Types de publication
Journal Article
Langues
eng
Pagination
906539Subventions
Organisme : NIA NIH HHS
ID : P30 AG072947
Pays : United States
Informations de copyright
Copyright © 2022 Brinkley, Leng, Register, Neth, Zetterberg, Blennow and Craft.
Déclaration de conflit d'intérêts
HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave and has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche. KB has served as a consultant, on advisory boards, or on data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Geriatr Soc. 2008 Jan;56(1):111-6
pubmed: 18028342
J Alzheimers Dis. 2017;57(3):953-968
pubmed: 28304301
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Atherosclerosis. 2017 Apr;259:41-45
pubmed: 28285092
Neurobiol Aging. 2012 Aug;33(8):1599-608
pubmed: 21684041
Neurobiol Aging. 2012 Feb;33(2):425.e19-27
pubmed: 21130529
Neurol Neuroimmunol Neuroinflamm. 2018 Nov 07;6(1):e512
pubmed: 30568991
Int J Obes (Lond). 2017 May;41(5):683-688
pubmed: 28104915
Clin Neuropathol. 2009 Jan-Feb;28(1):40-5
pubmed: 19216219
Mol Psychiatry. 2016 Jul;21(7):910-5
pubmed: 26324099
Clin Diabetes. 2015 Apr;33(2):97-111
pubmed: 25897193
Crit Rev Food Sci Nutr. 2022;62(13):3644-3657
pubmed: 33443451
Am J Geriatr Psychiatry. 2016 Sep;24(9):729-37
pubmed: 27421618
Arch Neurol. 2005 Oct;62(10):1556-60
pubmed: 16216938
Neurology. 2011 May 3;76(18):1568-74
pubmed: 21536637
Brain Res Rev. 2009 Mar;59(2):293-315
pubmed: 18845187
J Nutr Health Aging. 2017;21(3):284-291
pubmed: 28244568
J Alzheimers Dis. 2015;43(3):739-55
pubmed: 25147111
Int J Obes (Lond). 2009 Aug;33(8):893-8
pubmed: 19506566
J Nutr. 2001 Jan;131(1):132-46
pubmed: 11208950
Front Neurol. 2014 Apr 29;5:63
pubmed: 24808888
Obesity (Silver Spring). 2015 May;23(5):1092-6
pubmed: 25919926
J Alzheimers Dis. 2014;38(1):201-9
pubmed: 23948937
Curr Neuropharmacol. 2018;16(7):1059-1085
pubmed: 29046155
Alzheimers Dement. 2015 Dec;11(12):1417-1429
pubmed: 25960448
Neuroimage Clin. 2014 Sep 26;6:307-11
pubmed: 25379443
J Alzheimers Dis. 2015;48(3):825-32
pubmed: 26402111
Diabetologia. 2005 Feb;48(2):301-8
pubmed: 15660262
Ann Neurol. 2010 Aug;68(2):136-44
pubmed: 20695006
Mol Aspects Med. 2013 Feb;34(1):1-11
pubmed: 23068073
Biochim Biophys Acta. 2016 May;1862(5):966-74
pubmed: 26546479
J Gerontol A Biol Sci Med Sci. 2009 Jan;64(1):103-9
pubmed: 19168781
Nutr Metab (Lond). 2005 Oct 17;2:28
pubmed: 16229744
Acta Neuropathol. 2018 Sep;136(3):363-376
pubmed: 29700597
Front Aging Neurosci. 2011 Sep 13;3:12
pubmed: 21949507
Lancet Neurol. 2014 Sep;13(9):913-23
pubmed: 25142458
Int J Obes (Lond). 2022 May;46(5):1059-1067
pubmed: 35145215
Circulation. 2007 Jul 3;116(1):39-48
pubmed: 17576866
Acta Neurol Scand. 2011 Aug;124(2):122-9
pubmed: 20880294
Int Psychogeriatr. 2004 Sep;16(3):327-36
pubmed: 15559756
Aging Clin Exp Res. 2003 Aug;15(4):321-7
pubmed: 14661824
BMC Neurol. 2005 Dec 02;5:23
pubmed: 16321166
J Alzheimers Dis. 2016 Jun 18;53(3):1097-105
pubmed: 27340843
Neurobiol Aging. 2020 Feb;86:54-63
pubmed: 31757576
Arch Neurol. 2009 Mar;66(3):336-42
pubmed: 19273752
BMJ Open. 2013 Jan 24;3(1):
pubmed: 23355665
Neurology. 2004 Nov 23;63(10):1876-81
pubmed: 15557505
J Appl Physiol (1985). 2008 Mar;104(3):700-7
pubmed: 18079271
Obesity (Silver Spring). 2010 Dec;18(12):2354-61
pubmed: 20395951
Arch Neurol. 2007 Mar;64(3):392-8
pubmed: 17353383